{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:20:12Z","timestamp":1790104812293,"version":"4.0.1"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82400922"],"award-info":[{"award-number":["82400922"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82400922"],"award-info":[{"award-number":["82400922"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82400922"],"award-info":[{"award-number":["82400922"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82400922"],"award-info":[{"award-number":["82400922"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Provincial Natural Science Foundation of Liaoning","award":["2022-BS-120"],"award-info":[{"award-number":["2022-BS-120"]}]},{"name":"Provincial Natural Science Foundation of Liaoning","award":["2022-BS-120"],"award-info":[{"award-number":["2022-BS-120"]}]},{"name":"Provincial Natural Science Foundation of Liaoning","award":["2022-BS-120"],"award-info":[{"award-number":["2022-BS-120"]}]},{"name":"Provincial Natural Science Foundation of Liaoning","award":["2022-BS-120"],"award-info":[{"award-number":["2022-BS-120"]}]},{"name":"345 Talent Project of Shengjing Hospital of China Medical University","award":["M1349"],"award-info":[{"award-number":["M1349"]}]},{"name":"345 Talent Project of Shengjing Hospital of China Medical University","award":["M1349"],"award-info":[{"award-number":["M1349"]}]},{"name":"345 Talent Project of Shengjing Hospital of China Medical University","award":["M1349"],"award-info":[{"award-number":["M1349"]}]},{"name":"345 Talent Project of Shengjing Hospital of China Medical University","award":["M1349"],"award-info":[{"award-number":["M1349"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"DOI":"10.1186\/s12944-025-02474-0","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T08:19:26Z","timestamp":1740644366000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Hypothyroidism\/subclinical hypothyroidism and metabolic dysfunction-associated steatotic liver disease: advances in mechanism and treatment"],"prefix":"10.1186","volume":"24","author":[{"given":"Sicheng","family":"Pu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binbin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejiao","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"key":"2474_CR1","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/nrendo.2018.18","volume":"14","author":"PN Taylor","year":"2018","unstructured":"Taylor PN, Albrecht D, Scholz A, Gutierrez-Buey G, Lazarus JH, Dayan CM, Okosieme OE. Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol. 2018;14:301\u201316.","journal-title":"Nat Rev Endocrinol"},{"key":"2474_CR2","doi-asserted-by":"crossref","unstructured":"LeFevre ML: Screening for thyroid dysfunction: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2015;162:641\u2013650.","DOI":"10.7326\/M15-0483"},{"key":"2474_CR3","first-page":"153","volume":"322","author":"B Biondi","year":"2019","unstructured":"Biondi B, Cappola AR, Cooper DS. Subclinical Hypothyroidism: A Review Jama. 2019;322:153\u201360.","journal-title":"Subclinical Hypothyroidism: A Review Jama"},{"key":"2474_CR4","doi-asserted-by":"crossref","unstructured":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia. 2016;59:1121\u20131140.","DOI":"10.1007\/s00125-016-3902-y"},{"key":"2474_CR5","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73\u201384.","journal-title":"Hepatology"},{"key":"2474_CR6","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397:2212\u201324.","journal-title":"Lancet"},{"key":"2474_CR7","first-page":"1022","volume":"2019","author":"CM Association","year":"2019","unstructured":"Association CM, House CMJP. Practice CSoG, Association EBoCJoGPoCM, Disease EGoGfPCoES: Guideline for primary care of hypothyroidism. Chinese Journal of General Practitioners. 2019;2019:1022\u20138.","journal-title":"Chinese Journal of General Practitioners"},{"key":"2474_CR8","doi-asserted-by":"crossref","unstructured":"Mavromati M, Jornayvaz FR. Hypothyroidism-Associated Dyslipidemia: Potential Molecular Mechanisms Leading to NAFLD.\u00a0Int\u00a0J\u00a0Mol\u00a0Sci.\u00a02021;22:12797.","DOI":"10.3390\/ijms222312797"},{"key":"2474_CR9","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1210\/jc.2016-1300","volume":"101","author":"A Bano","year":"2016","unstructured":"Bano A, Chaker L, Plompen EP, Hofman A, Dehghan A, Franco OH, Janssen HL, Darwish Murad S, Peeters RP. Thyroid Function and the Risk of Nonalcoholic Fatty Liver Disease: The Rotterdam Study. J Clin Endocrinol Metab. 2016;101:3204\u201311.","journal-title":"J Clin Endocrinol Metab"},{"key":"2474_CR10","doi-asserted-by":"publisher","first-page":"e25738","DOI":"10.1097\/MD.0000000000025738","volume":"100","author":"X Zeng","year":"2021","unstructured":"Zeng X, Li B, Zou Y. The relationship between non-alcoholic fatty liver disease and hypothyroidism: A systematic review and meta-analysis. Medicine (Baltimore). 2021;100:e25738.","journal-title":"Medicine (Baltimore)"},{"key":"2474_CR11","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/j.dld.2018.08.012","volume":"50","author":"Z Guo","year":"2018","unstructured":"Guo Z, Li M, Han B, Qi X. Association of non-alcoholic fatty liver disease with thyroid function: A systematic review and meta-analysis. Dig Liver Dis. 2018;50:1153\u201362.","journal-title":"Dig Liver Dis"},{"key":"2474_CR12","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1089\/thy.2018.0257","volume":"28","author":"A Mantovani","year":"2018","unstructured":"Mantovani A, Nascimbeni F, Lonardo A, Zoppini G, Bonora E, Mantzoros CS, Targher G. Association Between Primary Hypothyroidism and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Thyroid. 2018;28:1270\u201384.","journal-title":"Thyroid"},{"key":"2474_CR13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12902-015-0030-5","volume":"15","author":"U Ludwig","year":"2015","unstructured":"Ludwig U, Holzner D, Denzer C, Greinert A, Haenle MM, Oeztuerk S, Koenig W, Boehm BO, Mason RA, Kratzer W, Graeter T. Subclinical and clinical hypothyroidism and non-alcoholic fatty liver disease: a cross-sectional study of a random population sample aged 18 to 65 years. BMC Endocr Disord. 2015;15:41.","journal-title":"BMC Endocr Disord"},{"key":"2474_CR14","doi-asserted-by":"publisher","first-page":"643582","DOI":"10.3389\/fcell.2021.643582","volume":"9","author":"S Qiu","year":"2021","unstructured":"Qiu S, Cao P, Guo Y, Lu H, Hu Y. Exploring the Causality Between Hypothyroidism and Non-alcoholic Fatty Liver: A Mendelian Randomization Study. Front Cell Dev Biol. 2021;9:643582.","journal-title":"Front Cell Dev Biol"},{"key":"2474_CR15","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.14309\/ajg.0000000000000654","volume":"115","author":"D Kim","year":"2020","unstructured":"Kim D, Vazquez-Montesino LM, Escober JA, Fernandes CT, Cholankeril G, Loomba R, Harrison SA, Younossi ZM, Ahmed A. Low Thyroid Function in Nonalcoholic Fatty Liver Disease Is an Independent Predictor of All-Cause and Cardiovascular Mortality. Am J Gastroenterol. 2020;115:1496\u2013504.","journal-title":"Am J Gastroenterol"},{"key":"2474_CR16","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3350\/cmh.2015.21.4.372","volume":"21","author":"KW Lee","year":"2015","unstructured":"Lee KW, Bang KB, Rhee EJ, Kwon HJ, Lee MY, Cho YK. Impact of hypothyroidism on the development of non-alcoholic fatty liver disease: A 4-year retrospective cohort study. Clin Mol Hepatol. 2015;21:372\u20138.","journal-title":"Clin Mol Hepatol"},{"key":"2474_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.medcli.2019.03.018","volume":"154","author":"A Mart\u00ednez Escud\u00e9","year":"2020","unstructured":"Mart\u00ednez Escud\u00e9 A, Pera G, Arteaga I, Exp\u00f3sito C, Rodr\u00edguez L, Tor\u00e1n P, Caballeria L. Relationship between hypothyroidism and non-alcoholic fatty liver disease in the Spanish population. Med Clin (Barc). 2020;154:1\u20136.","journal-title":"Med Clin (Barc)"},{"key":"2474_CR18","doi-asserted-by":"publisher","first-page":"e13038","DOI":"10.1002\/jgh3.13038","volume":"8","author":"S Wang","year":"2024","unstructured":"Wang S, Xia D, Fan H, Liu Z, Chen R, Suo C, Zhang T. Low thyroid function is associated with metabolic dysfunction-associated steatotic liver disease. JGH Open. 2024;8:e13038.","journal-title":"JGH Open"},{"key":"2474_CR19","doi-asserted-by":"publisher","first-page":"e434","DOI":"10.1210\/clinem\/dgad016","volume":"108","author":"YL Chen","year":"2023","unstructured":"Chen YL, Tian S, Wu J, Li H, Li S, Xu Z, Liang XY, Adhikari VP, Xiao J, Song JY, et al. Impact of Thyroid Function on the Prevalence and Mortality of Metabolic Dysfunction-Associated Fatty Liver Disease. J Clin Endocrinol Metab. 2023;108:e434\u201343.","journal-title":"J Clin Endocrinol Metab"},{"key":"2474_CR20","unstructured":"R M, R M, S R, Ganga R: To Assess Non Alcoholic Fatty Liver Disease in Patients with Clinical and Subclinical Hypothyroidism. J Assoc Physicians India. 2023;71:1."},{"key":"2474_CR21","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/j.jhep.2012.05.025","volume":"57","author":"L Xu","year":"2012","unstructured":"Xu L, Ma H, Miao M, Li Y. Impact of subclinical hypothyroidism on the development of non-alcoholic fatty liver disease: a prospective case-control study. J Hepatol. 2012;57:1153\u20134.","journal-title":"J Hepatol"},{"key":"2474_CR22","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jhep.2012.02.027","volume":"57","author":"GE Chung","year":"2012","unstructured":"Chung GE, Kim D, Kim W, Yim JY, Park MJ, Kim YJ, Yoon JH, Lee HS. Non-alcoholic fatty liver disease across the spectrum of hypothyroidism. J Hepatol. 2012;57:150\u20136.","journal-title":"J Hepatol"},{"key":"2474_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12876-022-02612-3","volume":"23","author":"H Fan","year":"2023","unstructured":"Fan H, Li L, Liu Z, Zhang P, Wu S, Han X, Chen X, Suo C, Cao L, Zhang T. Low thyroid function is associated with an increased risk of advanced fibrosis in patients with metabolic dysfunction-associated fatty liver disease. BMC Gastroenterol. 2023;23:3.","journal-title":"BMC Gastroenterol"},{"key":"2474_CR24","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s12098-020-03463-0","volume":"88","author":"R Patel","year":"2021","unstructured":"Patel R, Dave C, Mehta S, Mendpara H, Shukla R, Bajpai A. Metabolic Impact of Subclinical Hypothyroidism in Obese Children and Adolescents. Indian J Pediatr. 2021;88:437\u201340.","journal-title":"Indian J Pediatr"},{"key":"2474_CR25","doi-asserted-by":"publisher","first-page":"e1008","DOI":"10.1097\/MEG.0000000000002136","volume":"33","author":"SH Loosen","year":"2021","unstructured":"Loosen SH, Demir M, Kostev K, Luedde T, Roderburg C. Incidences of hypothyroidism and autoimmune thyroiditis are increased in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2021;33:e1008\u201312.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2474_CR26","doi-asserted-by":"publisher","first-page":"1173826","DOI":"10.3389\/fendo.2023.1173826","volume":"14","author":"Y Wen","year":"2023","unstructured":"Wen Y, Zhang H, Yang N, Gao X, Chen Z, Liu J, Wang G. Serum IL-27 levels increase in subjects with hypothyroidism and are negatively correlated with the occurrence of nonalcoholic fatty liver disease. Front Endocrinol (Lausanne). 2023;14:1173826.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2474_CR27","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1159\/000454920","volume":"6","author":"V Jaruvongvanich","year":"2017","unstructured":"Jaruvongvanich V, Sanguankeo A, Upala S. Nonalcoholic Fatty Liver Disease Is Not Associated with Thyroid Hormone Levels and Hypothyroidism: A Systematic Review and Meta-Analysis. Eur Thyroid J. 2017;6:208\u201315.","journal-title":"Eur Thyroid J"},{"key":"2474_CR28","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1038\/s41598-024-53112-1","volume":"14","author":"J Yuan","year":"2024","unstructured":"Yuan J, Zhang J, Luo Q, Peng L. Effects of nonalcoholic fatty liver disease on sarcopenia: evidence from genetic methods. Sci Rep. 2024;14:2709.","journal-title":"Sci Rep"},{"key":"2474_CR29","doi-asserted-by":"publisher","first-page":"15647","DOI":"10.1038\/s41598-021-95108-1","volume":"11","author":"X Sun","year":"2021","unstructured":"Sun X, Liu Z, Chen F, Du T. Sarcopenia modifies the associations of nonalcoholic fatty liver disease with all-cause and cardiovascular mortality among older adults. Sci Rep. 2021;11:15647.","journal-title":"Sci Rep"},{"key":"2474_CR30","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1111\/jgs.16416","volume":"68","author":"C Szlejf","year":"2020","unstructured":"Szlejf C, Suemoto CK, Janovsky C, Barreto SM, Diniz M, Lotufo PA, Bensenor IM. Thyroid Function and Sarcopenia: Results from the ELSA-Brasil Study. J Am Geriatr Soc. 2020;68:1545\u201353.","journal-title":"J Am Geriatr Soc"},{"key":"2474_CR31","doi-asserted-by":"publisher","first-page":"1378757","DOI":"10.3389\/fendo.2024.1378757","volume":"15","author":"J Wei","year":"2024","unstructured":"Wei J, Hou S, Hei P, Wang G. Thyroid dysfunction and sarcopenia: a two-sample Mendelian randomization study. Front Endocrinol (Lausanne). 2024;15:1378757.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2474_CR32","doi-asserted-by":"publisher","first-page":"1406165","DOI":"10.3389\/fendo.2024.1406165","volume":"15","author":"R Xu","year":"2024","unstructured":"Xu R, Li YY, Xu H. Mendelian randomization analysis reveals no causal relationship between thyroid function and sarcopenia-related traits. Front Endocrinol (Lausanne). 2024;15:1406165.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2474_CR33","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1007\/s11739-023-03339-z","volume":"18","author":"G Tarantino","year":"2023","unstructured":"Tarantino G, Sinatti G, Citro V, Santini SJ, Balsano C. Sarcopenia, a condition shared by various diseases: can we alleviate or delay the progression? Intern Emerg Med. 2023;18:1887\u201395.","journal-title":"Intern Emerg Med"},{"key":"2474_CR34","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.tem.2022.08.001","volume":"33","author":"E Hatziagelaki","year":"2022","unstructured":"Hatziagelaki E, Paschou SA, Sch\u00f6n M, Psaltopoulou T, Roden M. NAFLD and thyroid function: pathophysiological and therapeutic considerations. Trends Endocrinol Metab. 2022;33:755\u201368.","journal-title":"Trends Endocrinol Metab"},{"key":"2474_CR35","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","volume":"24","author":"SL Friedman","year":"2018","unstructured":"Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24:908\u201322.","journal-title":"Nat Med"},{"key":"2474_CR36","doi-asserted-by":"crossref","unstructured":"Benenati N, Bufano A, Cantara S, Ricci C, Marzocchi C, Ciuoli C, Sannino I, Tirone A, Voglino C, Vuolo G, Castagna MG: Type 2 deiodinase p.Thr92Ala polymorphism does not affect the severity of obesity and weight loss after bariatric surgery. Sci Rep. 2022;12:10643.","DOI":"10.1038\/s41598-022-14863-x"},{"key":"2474_CR37","doi-asserted-by":"publisher","first-page":"803363","DOI":"10.3389\/fendo.2021.803363","volume":"12","author":"FCB Oliveira","year":"2021","unstructured":"Oliveira FCB, Bauer EJ, Ribeiro CM, Pereira SA, Beserra BTS, Wajner SM, Maia AL, Neves FAR, Coelho MS, Amato AA. Liraglutide Activates Type 2 Deiodinase and Enhances \u03b23-Adrenergic-Induced Thermogenesis in Mouse Adipose Tissue. Front Endocrinol (Lausanne). 2021;12:803363.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2474_CR38","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrendo.2018.10","volume":"14","author":"RA Sinha","year":"2018","unstructured":"Sinha RA, Singh BK, Yen PM. Direct effects of thyroid hormones on hepatic lipid metabolism. Nat Rev Endocrinol. 2018;14:259\u201369.","journal-title":"Nat Rev Endocrinol"},{"key":"2474_CR39","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1152\/physrev.00030.2013","volume":"94","author":"R Mullur","year":"2014","unstructured":"Mullur R, Liu YY, Brent GA. Thyroid hormone regulation of metabolism. Physiol Rev. 2014;94:355\u201382.","journal-title":"Physiol Rev"},{"key":"2474_CR40","doi-asserted-by":"publisher","first-page":"697","DOI":"10.3945\/an.113.004648","volume":"4","author":"DG Mashek","year":"2013","unstructured":"Mashek DG. Hepatic fatty acid trafficking: multiple forks in the road. Adv Nutr. 2013;4:697\u2013710.","journal-title":"Adv Nutr"},{"key":"2474_CR41","doi-asserted-by":"crossref","unstructured":"Chen Y, Zhang J, Cui W, Silverstein RL. CD36, a signaling receptor and fatty acid transporter that regulates immune cell metabolism and fate.\u00a0J Exp Med.\u00a02022;219:e20211314.","DOI":"10.1084\/jem.20211314"},{"key":"2474_CR42","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41573-021-00367-2","volume":"21","author":"B Batchuluun","year":"2022","unstructured":"Batchuluun B, Pinkosky SL, Steinberg GR. Lipogenesis inhibitors: therapeutic opportunities and challenges. Nat Rev Drug Discov. 2022;21:283\u2013305.","journal-title":"Nat Rev Drug Discov"},{"key":"2474_CR43","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s13238-017-0409-3","volume":"9","author":"J Han","year":"2018","unstructured":"Han J, Wang Y. mTORC1 signaling in hepatic lipid metabolism. Protein Cell. 2018;9:145\u201351.","journal-title":"Protein Cell"},{"key":"2474_CR44","doi-asserted-by":"publisher","first-page":"107598","DOI":"10.1016\/j.celrep.2020.107598","volume":"31","author":"A Guilherme","year":"2020","unstructured":"Guilherme A, Yenilmez B, Bedard AH, Henriques F, Liu D, Lee A, Goldstein L, Kelly M, Nicoloro SM, Chen M, et al. Control of Adipocyte Thermogenesis and Lipogenesis through \u03b23-Adrenergic and Thyroid Hormone Signal Integration. Cell Rep. 2020;31:107598.","journal-title":"Cell Rep"},{"key":"2474_CR45","doi-asserted-by":"crossref","unstructured":"Zhang D, Wei Y, Huang Q, Chen Y, Zeng K, Yang W, Chen J, Chen J. Important Hormones Regulating Lipid Metabolism. Molecules. 2022;27:7052.","DOI":"10.3390\/molecules27207052"},{"key":"2474_CR46","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1080\/15548627.2020.1728097","volume":"17","author":"W Cui","year":"2021","unstructured":"Cui W, Sathyanarayan A, Lopresti M, Aghajan M, Chen C, Mashek DG. Lipophagy-derived fatty acids undergo extracellular efflux via lysosomal exocytosis. Autophagy. 2021;17:690\u2013705.","journal-title":"Autophagy"},{"key":"2474_CR47","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1172\/JCI60580","volume":"122","author":"RA Sinha","year":"2012","unstructured":"Sinha RA, You SH, Zhou J, Siddique MM, Bay BH, Zhu X, Privalsky ML, Cheng SY, Stevens RD, Summers SA, et al. Thyroid hormone stimulates hepatic lipid catabolism via activation of autophagy. J Clin Invest. 2012;122:2428\u201338.","journal-title":"J Clin Invest"},{"key":"2474_CR48","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.apsb.2021.07.021","volume":"12","author":"K Byrnes","year":"2022","unstructured":"Byrnes K, Blessinger S, Bailey NT, Scaife R, Liu G, Khambu B. Therapeutic regulation of autophagy in hepatic metabolism. Acta Pharm Sin B. 2022;12:33\u201349.","journal-title":"Acta Pharm Sin B"},{"key":"2474_CR49","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.bbrc.2023.04.061","volume":"662","author":"YH Tseng","year":"2023","unstructured":"Tseng YH, Chang CC, Lin KH. Thyroid hormone upregulates LAMP2 expression and lysosome activity. Biochem Biophys Res Commun. 2023;662:66\u201375.","journal-title":"Biochem Biophys Res Commun"},{"key":"2474_CR50","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12929-019-0517-x","volume":"26","author":"HC Chi","year":"2019","unstructured":"Chi HC, Tsai CY, Tsai MM, Yeh CT, Lin KH. Molecular functions and clinical impact of thyroid hormone-triggered autophagy in liver-related diseases. J Biomed Sci. 2019;26:24.","journal-title":"J Biomed Sci"},{"key":"2474_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mce.2011.05.009","volume":"342","author":"JM Weitzel","year":"2011","unstructured":"Weitzel JM, Iwen KA. Coordination of mitochondrial biogenesis by thyroid hormone. Mol Cell Endocrinol. 2011;342:1\u20137.","journal-title":"Mol Cell Endocrinol"},{"key":"2474_CR52","doi-asserted-by":"crossref","unstructured":"Singh BK, Sinha RA, Tripathi M, Mendoza A, Ohba K, Sy JAC, Xie SY, Zhou J, Ho JP, Chang C-y, et al. Thyroid hormone receptor and ERR\u03b1 coordinately regulate mitochondrial fission, mitophagy, biogenesis, and function.\u00a0Sci\u00a0Signal.\u00a02018;11:eaam5855.","DOI":"10.1126\/scisignal.aam5855"},{"key":"2474_CR53","doi-asserted-by":"publisher","first-page":"5148","DOI":"10.1093\/nar\/29.24.5148","volume":"29","author":"JM Weitzel","year":"2001","unstructured":"Weitzel JM, Radtke C, Seitz HJ. Two thyroid hormone-mediated gene expression patterns in vivo identified by cDNA expression arrays in rat. Nucleic Acids Res. 2001;29:5148\u201355.","journal-title":"Nucleic Acids Res"},{"key":"2474_CR54","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1074\/jbc.M112.437970","volume":"288","author":"S Thakran","year":"2013","unstructured":"Thakran S, Sharma P, Attia RR, Hori RT, Deng X, Elam MB, Park EA. Role of sirtuin 1 in the regulation of hepatic gene expression by thyroid hormone. J Biol Chem. 2013;288:807\u201318.","journal-title":"J Biol Chem"},{"key":"2474_CR55","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1080\/15548627.2015.1061849","volume":"11","author":"RA Sinha","year":"2015","unstructured":"Sinha RA, Singh BK, Zhou J, Wu Y, Farah BL, Ohba K, Lesmana R, Gooding J, Bay BH, Yen PM. Thyroid hormone induction of mitochondrial activity is coupled to mitophagy via ROS-AMPK-ULK1 signaling. Autophagy. 2015;11:1341\u201357.","journal-title":"Autophagy"},{"key":"2474_CR56","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1002\/hep.31296","volume":"72","author":"MJ Ritter","year":"2020","unstructured":"Ritter MJ, Amano I, Hollenberg AN. Thyroid Hormone Signaling and the Liver. Hepatology. 2020;72:742\u201352.","journal-title":"Hepatology"},{"key":"2474_CR57","doi-asserted-by":"publisher","first-page":"511","DOI":"10.3389\/fendo.2018.00511","volume":"9","author":"LH Duntas","year":"2018","unstructured":"Duntas LH, Brenta G. A Renewed Focus on the Association Between Thyroid Hormones and Lipid Metabolism. Front Endocrinol (Lausanne). 2018;9:511.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2474_CR58","doi-asserted-by":"publisher","first-page":"10297","DOI":"10.1073\/pnas.0504379102","volume":"102","author":"L Johansson","year":"2005","unstructured":"Johansson L, Rudling M, Scanlan TS, Lund\u00e5sen T, Webb P, Baxter J, Angelin B, Parini P. Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice. Proc Natl Acad Sci U S A. 2005;102:10297\u2013302.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2474_CR59","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1073\/pnas.0705286104","volume":"105","author":"A Berkenstam","year":"2008","unstructured":"Berkenstam A, Kristensen J, Mellstr\u00f6m K, Carlsson B, Malm J, Rehnmark S, Garg N, Andersson CM, Rudling M, Sj\u00f6berg F, et al. The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans. Proc Natl Acad Sci U S A. 2008;105:663\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2474_CR60","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1210\/er.2018-00275","volume":"40","author":"AC Bianco","year":"2019","unstructured":"Bianco AC, Dumitrescu A, Gereben B, Ribeiro MO, Fonseca TL, Fernandes GW, Bocco B. Paradigms of Dynamic Control of Thyroid Hormone Signaling. Endocr Rev. 2019;40:1000\u201347.","journal-title":"Endocr Rev"},{"key":"2474_CR61","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1210\/er.2009-0007","volume":"31","author":"SY Cheng","year":"2010","unstructured":"Cheng SY, Leonard JL, Davis PJ. Molecular aspects of thyroid hormone actions. Endocr Rev. 2010;31:139\u201370.","journal-title":"Endocr Rev"},{"key":"2474_CR62","doi-asserted-by":"crossref","unstructured":"Santillana N, Astudillo-Guerrero C, D\u2019Espessailles A, Cruz G. White Adipose Tissue Dysfunction: Pathophysiology and Emergent Measurements. Nutrients. 2023;15:1722.","DOI":"10.3390\/nu15071722"},{"key":"2474_CR63","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1161\/CIRCRESAHA.121.318093","volume":"128","author":"M Koenen","year":"2021","unstructured":"Koenen M, Hill MA, Cohen P, Sowers JR. Obesity, Adipose Tissue and Vascular Dysfunction. Circ Res. 2021;128:951\u201368.","journal-title":"Circ Res"},{"key":"2474_CR64","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.cmet.2017.12.002","volume":"27","author":"RK Zwick","year":"2018","unstructured":"Zwick RK, Guerrero-Juarez CF, Horsley V, Plikus MV. Anatomical, Physiological, and Functional Diversity of Adipose Tissue. Cell Metab. 2018;27:68\u201383.","journal-title":"Cell Metab"},{"key":"2474_CR65","doi-asserted-by":"publisher","first-page":"3394","DOI":"10.1038\/s41467-022-31154-1","volume":"13","author":"S Liu","year":"2022","unstructured":"Liu S, Shen S, Yan Y, Sun C, Lu Z, Feng H, Ma Y, Tang Z, Yu J, Wu Y, et al. Triiodothyronine (T3) promotes brown fat hyperplasia via thyroid hormone receptor \u03b1 mediated adipocyte progenitor cell proliferation. Nat Commun. 2022;13:3394.","journal-title":"Nat Commun"},{"key":"2474_CR66","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1080\/15548627.2018.1511263","volume":"15","author":"WW Yau","year":"2019","unstructured":"Yau WW, Singh BK, Lesmana R, Zhou J, Sinha RA, Wong KA, Wu Y, Bay BH, Sugii S, Sun L, Yen PM. Thyroid hormone (T(3)) stimulates brown adipose tissue activation via mitochondrial biogenesis and MTOR-mediated mitophagy. Autophagy. 2019;15:131\u201350.","journal-title":"Autophagy"},{"key":"2474_CR67","doi-asserted-by":"crossref","unstructured":"Yau WW, Yen PM. Thermogenesis in Adipose Tissue Activated by Thyroid Hormone.\u00a0Int\u00a0J\u00a0Mol\u00a0Sci.\u00a02020;21:3020.","DOI":"10.3390\/ijms21083020"},{"key":"2474_CR68","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1089\/thy.2015.0140","volume":"26","author":"G Brenta","year":"2016","unstructured":"Brenta G, Berg G, Miksztowicz V, Lopez G, Lucero D, Faingold C, Murakami M, Machima T, Nakajima K, Schreier L. Atherogenic Lipoproteins in Subclinical Hypothyroidism and Their Relationship with Hepatic Lipase Activity: Response to Replacement Treatment with Levothyroxine. Thyroid. 2016;26:365\u201372.","journal-title":"Thyroid"},{"key":"2474_CR69","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1210\/jc.2018-00475","volume":"103","author":"E Bruinstroop","year":"2018","unstructured":"Bruinstroop E, Dalan R, Cao Y, Bee YM, Chandran K, Cho LW, Soh SB, Teo EK, Toh SA, Leow MKS, et al. Low-Dose Levothyroxine Reduces Intrahepatic Lipid Content in Patients With Type 2 Diabetes Mellitus and NAFLD. J Clin Endocrinol Metab. 2018;103:2698\u2013706.","journal-title":"J Clin Endocrinol Metab"},{"key":"2474_CR70","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1089\/thy.2021.0621","volume":"32","author":"J Zhou","year":"2022","unstructured":"Zhou J, Tripathi M, Ho JP, Widjaja AA, Shekeran SG, Camat MD, James A, Wu Y, Ching J, Kovalik JP, et al. Thyroid Hormone Decreases Hepatic Steatosis, Inflammation, and Fibrosis in a Dietary Mouse Model of Nonalcoholic Steatohepatitis. Thyroid. 2022;32:725\u201338.","journal-title":"Thyroid"},{"key":"2474_CR71","doi-asserted-by":"publisher","first-page":"5753039","DOI":"10.1155\/2017\/5753039","volume":"2017","author":"L Liu","year":"2017","unstructured":"Liu L, Yu Y, Zhao M, Zheng D, Zhang X, Guan Q, Xu C, Gao L, Zhao J, Zhang H. Benefits of Levothyroxine Replacement Therapy on Nonalcoholic Fatty Liver Disease in Subclinical Hypothyroidism Patients. Int J Endocrinol. 2017;2017:5753039.","journal-title":"Int J Endocrinol"},{"key":"2474_CR72","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1634\/theoncologist.2015-0179","volume":"21","author":"M Papaleontiou","year":"2016","unstructured":"Papaleontiou M, Hawley ST, Haymart MR. Effect of Thyrotropin Suppression Therapy on Bone in Thyroid Cancer Patients. Oncologist. 2016;21:165\u201371.","journal-title":"Oncologist"},{"key":"2474_CR73","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1096\/fj.05-3977fje","volume":"19","author":"A Lanni","year":"2005","unstructured":"Lanni A, Moreno M, Lombardi A, de Lange P, Silvestri E, Ragni M, Farina P, Baccari GC, Fallahi P, Antonelli A, Goglia F. 3,5-diiodo-L-thyronine powerfully reduces adiposity in rats by increasing the burning of fats. Faseb j. 2005;19:1552\u20134.","journal-title":"Faseb j"},{"key":"2474_CR74","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.jhep.2009.03.023","volume":"51","author":"MP Mollica","year":"2009","unstructured":"Mollica MP, Lionetti L, Moreno M, Lombardi A, De Lange P, Antonelli A, Lanni A, Cavaliere G, Barletta A, Goglia F. 3,5-diiodo-l-thyronine, by modulating mitochondrial functions, reverses hepatic fat accumulation in rats fed a high-fat diet. J Hepatol. 2009;51:363\u201370.","journal-title":"J Hepatol"},{"key":"2474_CR75","first-page":"655","volume":"25","author":"A Antonelli","year":"2011","unstructured":"Antonelli A, Fallahi P, Ferrari SM, Di Domenicantonio A, Moreno M, Lanni A, Goglia F. 3,5-diiodo-L-thyronine increases resting metabolic rate and reduces body weight without undesirable side effects. J Biol Regul Homeost Agents. 2011;25:655\u201360.","journal-title":"J Biol Regul Homeost Agents"},{"key":"2474_CR76","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.1096\/fj.10-157115","volume":"24","author":"F Cioffi","year":"2010","unstructured":"Cioffi F, Zambad SP, Chhipa L, Senese R, Busiello RA, Tuli D, Munshi S, Moreno M, Lombardi A, Gupta RC, et al. TRC150094, a novel functional analog of iodothyronines, reduces adiposity by increasing energy expenditure and fatty acid oxidation in rats receiving a high-fat diet. Faseb j. 2010;24:3451\u201361.","journal-title":"Faseb j"},{"key":"2474_CR77","doi-asserted-by":"publisher","first-page":"615","DOI":"10.2147\/DMSO.S330515","volume":"15","author":"D Joshi","year":"2022","unstructured":"Joshi D, Gj P, Ghosh S, Mohanan A, Joshi S, Mohan V, Chowdhury S, Dutt C, Tandon N. TRC150094, a Novel Mitochondrial Modulator, Reduces Cardio-Metabolic Risk as an Add-On Treatment: a Phase-2, 24-Week, Multi-Center, Randomized, Double-Blind. Clinical Trial Diabetes Metab Syndr Obes. 2022;15:615\u201331.","journal-title":"Clinical Trial Diabetes Metab Syndr Obes"},{"key":"2474_CR78","doi-asserted-by":"publisher","first-page":"e86890","DOI":"10.1371\/journal.pone.0086890","volume":"9","author":"F van der Valk","year":"2014","unstructured":"van der Valk F, Hassing C, Visser M, Thakkar P, Mohanan A, Pathak K, Dutt C, Chauthaiwale V, Ackermans M, Nederveen A, et al. The effect of a diiodothyronine mimetic on insulin sensitivity in male cardiometabolic patients: a double-blind randomized controlled trial. PLoS ONE. 2014;9:e86890.","journal-title":"PLoS ONE"},{"key":"2474_CR79","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1210\/en.2003-0973","volume":"145","author":"GJ Grover","year":"2004","unstructured":"Grover GJ, Egan DM, Sleph PG, Beehler BC, Chiellini G, Nguyen NH, Baxter JD, Scanlan TS. Effects of the thyroid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates: selective actions relative to 3,5,3\u2019-triiodo-L-thyronine. Endocrinology. 2004;145:1656\u201361.","journal-title":"Endocrinology"},{"key":"2474_CR80","doi-asserted-by":"publisher","first-page":"E89","DOI":"10.1152\/ajpendo.00573.2012","volume":"305","author":"DF Vatner","year":"2013","unstructured":"Vatner DF, Weismann D, Beddow SA, Kumashiro N, Erion DM, Liao XH, Grover GJ, Webb P, Phillips KJ, Weiss RE, et al. Thyroid hormone receptor-\u03b2 agonists prevent hepatic steatosis in fat-fed rats but impair insulin sensitivity via discrete pathways. Am J Physiol Endocrinol Metab. 2013;305:E89-100.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2474_CR81","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/S2213-8587(14)70006-3","volume":"2","author":"B Sjouke","year":"2014","unstructured":"Sjouke B, Langslet G, Ceska R, Nicholls SJ, Nissen SE, \u00d6hlander M, Ladenson PW, Olsson AG, Hovingh GK, Kastelein JJ. Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study. Lancet Diabetes Endocrinol. 2014;2:455\u201363.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2474_CR82","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1089\/thy.2020.0071","volume":"30","author":"R Zucchi","year":"2020","unstructured":"Zucchi R. Thyroid Hormone Analogues: An Update. Thyroid. 2020;30:1099\u2013105.","journal-title":"Thyroid"},{"key":"2474_CR83","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/j.1750-3639.2009.00038.x","volume":"156","author":"BR Ito","year":"2009","unstructured":"Ito BR, Zhang BH, Cable EE, Song X, Fujitaki JM, MacKenna DA, Wilker CE, Chi B, van Poelje PD, Linemeyer DL, Erion MD. Thyroid hormone beta receptor activation has additive cholesterol lowering activity in combination with atorvastatin in rabbits, dogs and monkeys. Br J Pharmacol. 2009;156:454\u201365.","journal-title":"Br J Pharmacol"},{"key":"2474_CR84","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/17446651.2022.2110864","volume":"17","author":"EK Wirth","year":"2022","unstructured":"Wirth EK, Puengel T, Spranger J, Tacke F. Thyroid hormones as a disease modifier and therapeutic target in nonalcoholic steatohepatitis. Expert Rev Endocrinol Metab. 2022;17:425\u201334.","journal-title":"Expert Rev Endocrinol Metab"},{"key":"2474_CR85","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1089\/thy.2019.0007","volume":"29","author":"J Zhou","year":"2019","unstructured":"Zhou J, Waskowicz LR, Lim A, Liao XH, Lian B, Masamune H, Refetoff S, Tran B, Koeberl DD, Yen PM. A Liver-Specific Thyromimetic, VK2809, Decreases Hepatosteatosis in Glycogen Storage Disease Type Ia. Thyroid. 2019;29:1158\u201367.","journal-title":"Thyroid"},{"key":"2474_CR86","doi-asserted-by":"publisher","first-page":"e150","DOI":"10.1016\/S0618-8278(19)30266-X","volume":"70","author":"R Loomba","year":"2019","unstructured":"Loomba R, Neutel J, Mohseni R, Bernard D, Severance R, Dao M, Saini S, Margaritescu C, Homer K, Tran B, et al. LBP-20-VK2809, a Novel Liver-Directed Thyroid Receptor Beta Agonist, Significantly Reduces Liver Fat with Both Low and High Doses in Patients with Non-Alcoholic Fatty Liver Disease: A Phase 2 Randomized. Placebo-Controlled Trial Journal of Hepatology. 2019;70:e150\u20131.","journal-title":"Placebo-Controlled Trial Journal of Hepatology"},{"key":"2474_CR87","doi-asserted-by":"crossref","unstructured":"Caddeo A, Kowalik MA, Serra M, Runfola M, Bacci A, Rapposelli S, Columbano A, Perra A. TG68, a Novel Thyroid Hormone Receptor-\u03b2 Agonist for the Treatment of NAFLD.\u00a0Int\u00a0J\u00a0Mol\u00a0Sci.\u00a02021;22:13105.","DOI":"10.3390\/ijms222313105"},{"key":"2474_CR88","doi-asserted-by":"publisher","first-page":"1127517","DOI":"10.3389\/fonc.2023.1127517","volume":"13","author":"A Caddeo","year":"2023","unstructured":"Caddeo A, Serra M, Sedda F, Bacci A, Manera C, Rapposelli S, Columbano A, Perra A, Kowalik MA. Potential use of TG68 - A novel thyromimetic - for the treatment of non-alcoholic fatty liver (NAFLD)-associated hepatocarcinogenesis. Front Oncol. 2023;13:1127517.","journal-title":"Front Oncol"},{"key":"2474_CR89","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","volume":"394","author":"SA Harrison","year":"2019","unstructured":"Harrison SA, Bashir MR, Guy CD, Zhou R, Moylan CA, Frias JP, Alkhouri N, Bansal MB, Baum S, Neuschwander-Tetri BA, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2019;394:2012\u201324.","journal-title":"Lancet"},{"key":"2474_CR90","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/j.cgh.2021.07.039","volume":"20","author":"ZM Younossi","year":"2022","unstructured":"Younossi ZM, Stepanova M, Taub RA, Barbone JM, Harrison SA. Hepatic Fat Reduction Due to Resmetirom in Patients With Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of Life. Clin Gastroenterol Hepatol. 2022;20:1354-1361.e1357.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2474_CR91","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","volume":"29","author":"SA Harrison","year":"2023","unstructured":"Harrison SA, Taub R, Neff GW, Lucas KJ, Labriola D, Moussa SE, Alkhouri N, Bashir MR. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med. 2023;29:2919\u201328.","journal-title":"Nat Med"},{"key":"2474_CR92","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, Labriola D, Moussa SE, Neff GW, Rinella ME, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024;390:497\u2013509.","journal-title":"N Engl J Med"},{"key":"2474_CR93","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1111\/bph.15427","volume":"178","author":"A Kannt","year":"2021","unstructured":"Kannt A, Wohlfart P, Madsen AN, Veidal SS, Feigh M, Schmoll D. Activation of thyroid hormone receptor-\u03b2 improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis. Br J Pharmacol. 2021;178:2412\u201323.","journal-title":"Br J Pharmacol"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-025-02474-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-025-02474-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-025-02474-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T08:53:48Z","timestamp":1740646428000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-025-02474-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":93,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2474"],"URL":"https:\/\/doi.org\/10.1186\/s12944-025-02474-0","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]},"assertion":[{"value":"13 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"75"}}